7,565 press releases indexed under healthcare.
The global antimicrobial urinary catheters market was valued at USD 1.2 billion in 2025 and is expected to reach USD 2.3 billion by 2033, expanding [read full press release...]
Gold Coast, Australia, 2026-09-10 — /EPR Network/ — As Australia observes Body Image and Eating Disorders Awareness Week (BIEDAW) from 1–7 September 2024, the Butterfly Foundation [read full press release...]
Former Acting Director of the White House Office of National Drug Control Policy Brings 28 Years of Federal Drug Policy and Addiction Expertise to BioCorRx ANAHEIM, CA - September 10, 2026 ( NEWMEDIAWIRE ) - BioCorRx Inc. (OTC: BICX) (the “Company”) , a developer and provider of innovative treatment support programs for substance use disorders and related conditions, today announced the appointment of Richard J. Baum to the Company’s Strategic Advisory Board. Baum is a former Acting Director of the White House Office of National Drug Control Policy (ONDCP) and former Executive Director of the President’s Commission on Combating Drug Addiction and the Opioid Crisis. Baum brings nearly three decades of experience in national drug policy, addiction, public health, law enforcement, and justice
TOKYO, Japan, 2026-09-10 — /EPR Network/ — MEDICAL JAPAN 2026 TOKYO, one of Japan’s largest healthcare trade shows, is set to bring together more than [read full press release...]
LINKÖPING, Sweden, Sept. 10, 2026 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed a contract to extend its Sectra One enterprise imaging solution, delivered as a fully managed cloud service, from hospitals in the Capital Region in...
The global cold plasma market was valued at USD 167.8 million in 2025 and is expected to reach USD 495.9 million by 2033, expanding at [read full press release...]
Why clean air matters - - Air pollution is a global health emergency. In 2023, it claimed 7.9 million lives, making it the second leading risk factor for mortality worldwide, ahead of tobacco and poor diet. Children, older people and those with existing health conditions carry the greatest risk, and the economic toll is estimated to be USD 8.1 trillion a year in healthcare costs, hospital visits and lost working days. - - But cities are proving this can change. Since signing the Clean... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=360278
White Paper shows how AdJane's clinically validated Nm-nOMV platform could add a proprietary mucosal component to existing intramuscular vaccination programs DELFT, The Netherlands, Sept. 10, 2026 /PRNewswire/ -- AdJane Biosciences ("AdJane"), a clinical-stage next-generation vaccine...
September 22 event will bring together healthcare professionals, public safety leaders and community organizations to connect seniors and families with health, safety and local resources. [PR.com]
Laur Zimmardi of Tucson, Arizona, has been recognized as a Woman of the Month for September 2026 by P.O.W.E.R. (Professional Organization of Women of Excellence Recognized). This prestigious distinction acknowledges her contributions and achievements in phlebotomy, education, entrepreneurship, and patient safety. In addition to this honor, Zimmardi was selected by P.O.W.E.R. to be showcased on the iconic Times Square [PR.com]
Om Uro and Eye Care, led by Dr. Neel Shah and Dr. Ritu Shah, now offers advanced urology and eye care services in Vadodara. The clinic addresses kidney stones, prostate disease, and comprehensive eye health.
Basel, 10 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for Enspryng® (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The filing acceptance is based on positive results from the Phase III METEOROID study, which showed that Enspryng provided consistent, clinically meaningful improvements for people living with MOGAD. 1 This marks the second FDA Priority Review for Enspryng, following the one granted for thyroid eye disease (TED) in June 2026. The FDA is expected to make a decision on approval in MOGAD by 10 January 2027.